TY - JOUR
T1 - Respiratory Viruses in Patients With Hematological Malignancy in Boreal Autumn/Winter 2023–2024
T2 - EPICOVIDEHA-EPIFLUEHA Report
AU - Salmanton-García, Jon
AU - Marchesi, Francesco
AU - Navrátil, Milan
AU - Piukovics, Klára
AU - del Principe, Maria Ilaria
AU - Criscuolo, Marianna
AU - Bilgin, Yavuz M.
AU - Fracchiolla, Nicola S.
AU - Vena, Antonio
AU - Romano, Alessandra
AU - Falces-Romero, Iker
AU - Sgherza, Nicola
AU - Heras-Fernando, Inmaculada
AU - Biernat, Monika M.
AU - Petzer, Verena
AU - Žák, Pavel
AU - Weinbergerová, Barbora
AU - Samarkos, Michail
AU - Erben, Nurettin
AU - van Praet, Jens
AU - López-García, Alberto
AU - Labrador, Jorge
AU - Lahmer, Tobias
AU - Drgoňa, Ľuboš
AU - Merelli, Maria
AU - Cuccaro, Annarosa
AU - Martín-Pérez, Sonia
AU - Dávila-Valls, Julio
AU - Farina, Francesca
AU - Cattaneo, Chiara
AU - Pinczés, László Imre
AU - Magyari, Ferenc
AU - Espigado, Ildefonso
AU - Buquicchio, Caterina
AU - Vinh, Donald C.
AU - Stoma, Igor
AU - Čerňan, Martin
AU - Prezioso, Lucia
AU - Papa, Mario Virgilio
AU - Plantefeve, Gaëtan
AU - Khedr, Reham Abdelaziz
AU - Batinić, Josip
AU - Magliano, Gabriele
AU - Erdem, Simge
AU - Khostelidi, Sofya
AU - Čolović, Natasha
AU - Nappi, Davide
AU - García-Ramírez, Patricia
AU - Góra, Jakub
AU - Bakker, Martijn
AU - Cornely, Oliver A
AU - Pagano, Livio
N1 - Publisher Copyright:
© 2024 The Author(s). American Journal of Hematology published by Wiley Periodicals LLC.
PY - 2024/12/23
Y1 - 2024/12/23
N2 - Community-acquired respiratory viral infections (CARV) significantly impact patients with hematological malignancies (HM), leading to high morbidity and mortality. However, large-scale, real-world data on CARV in these patients is limited. This study analyzed data from the EPICOVIDEHA-EPIFLUEHA registry, focusing on patients with HM diagnosed with CARV during the 2023–2024 autumn–winter season. The study assessed epidemiology, clinical characteristics, risk factors, and outcomes. The study examined 1312 patients with HM diagnosed with CARV during the 2023–2024 autumn–winter season. Of these, 59.5% required hospitalization, with 13.5% needing ICU admission. The overall mortality rate was 10.6%, varying by virus: parainfluenza (21.3%), influenza (8.8%), metapneumovirus (7.1%), RSV (5.9%), or SARS-CoV-2 (5.0%). Poor outcomes were significantly associated with smoking history, severe lymphopenia, secondary bacterial infections, and ICU admission. This study highlights the severe risk CARV poses to patients with HM, especially those undergoing active treatment. The high rates of hospitalization and mortality stress the need for better prevention, early diagnosis, and targeted therapies. Given the severe outcomes with certain viruses like parainfluenza, tailored strategies are crucial to improving patient outcomes in future CARV seasons.
AB - Community-acquired respiratory viral infections (CARV) significantly impact patients with hematological malignancies (HM), leading to high morbidity and mortality. However, large-scale, real-world data on CARV in these patients is limited. This study analyzed data from the EPICOVIDEHA-EPIFLUEHA registry, focusing on patients with HM diagnosed with CARV during the 2023–2024 autumn–winter season. The study assessed epidemiology, clinical characteristics, risk factors, and outcomes. The study examined 1312 patients with HM diagnosed with CARV during the 2023–2024 autumn–winter season. Of these, 59.5% required hospitalization, with 13.5% needing ICU admission. The overall mortality rate was 10.6%, varying by virus: parainfluenza (21.3%), influenza (8.8%), metapneumovirus (7.1%), RSV (5.9%), or SARS-CoV-2 (5.0%). Poor outcomes were significantly associated with smoking history, severe lymphopenia, secondary bacterial infections, and ICU admission. This study highlights the severe risk CARV poses to patients with HM, especially those undergoing active treatment. The high rates of hospitalization and mortality stress the need for better prevention, early diagnosis, and targeted therapies. Given the severe outcomes with certain viruses like parainfluenza, tailored strategies are crucial to improving patient outcomes in future CARV seasons.
KW - antiviral therapy
KW - community-acquired respiratory viral infection
KW - hematological malignancy
KW - secondary infection
KW - vaccine coverage
UR - http://www.scopus.com/inward/record.url?scp=85212774991&partnerID=8YFLogxK
U2 - 10.1002/ajh.27565
DO - 10.1002/ajh.27565
M3 - Article
AN - SCOPUS:85212774991
SN - 0361-8609
JO - American Journal of Hematology
JF - American Journal of Hematology
ER -